Early Trial Of New Drug MK-3475 Promising For Patients With Triple-Negative Breast Cancer
Wednesday, December 10, 2014 - 13:20
in Health & Medicine
A multi-center, non-randomized phase-Ib clinical trial designed to evaluate the safety, tolerability and antitumor activity of bi-weekly infusions of pembrolizumab (MK-3475, marketed as Keytruda®) found that infusion of pembrolizumab produced durable responses in almost one out of five patients. Patients with metastatic triple-negative breast cancer--a disease with no approved targeted therapies. In a presentation at the 2014 San Antonio Breast Cancer Symposium., the researchers discussed the study of 27 patients, aged 29 to 72 years, who had metastatic triple-negative breast cancer that either relapsed after treatment for early stage disease or progressed on therapy for advanced disease. read more